Last reviewed: October 11, 2026
Quick Answer
As of October 11, 2026, no peptide has been added to FDA's 503A Bulks List. An FDA advisory committee recommended six peptides on July 23 and 24, 2026, but that vote is advice and not a rule. A Federal Register search that day found no proposed or final rule touching 21 CFR part 216 since June 2025. A second committee meeting on five more peptides is expected before the end of February 2027. None of this changes how research use only material is labeled or sold.
Key Takeaways
- The 503A Bulks List in 21 CFR 216.23(a) still names six substances, and none of them is a peptide [1].
- The July 2026 committee voted in favor of six peptides and against one, emideltide. Those votes are non-binding [2].
- FDA's own review staff had recommended against adding all seven [2].
- Removal from Category 2 on April 15, 2026 lifted a safety flag. It did not make any peptide eligible for compounding [3].
- FDA dated five warning letters to online peptide sellers on August 24, 2026 [4].
- Anti-doping rules run on a separate track. The 2027 WADA list takes effect on January 1, 2027 [5].
Why this page exists
Peptide news moves fast and gets repeated badly. A committee vote becomes "FDA approval" in a headline. A removed safety flag becomes "now legal" in a seller's ad.
We keep one dated page that puts the main pieces side by side. Each row says what the rule governs, where it stands, and where to read more. Where a row needs depth, we link to the full article instead of repeating it here.
This page reports public regulatory records. It does not tell anyone how to obtain or use a product, and it makes no claim about any compound's safety or effect.
Where each pathway stands today
Five different systems get mixed together in peptide coverage. Drug approval, pharmacy compounding, enforcement, scheduling, and sport anti-doping each answer a different question. The table keeps them apart.
Pathway | What it decides | Status as of October 11, 2026 | Read more |
|---|---|---|---|
FDA drug approval | Whether a peptide can be marketed as a medicine | BPC-157, TB-500, KPV, MOTS-c, epitalon, semax, ipamorelin, CJC-1295 and GHK-Cu hold no FDA approval for any indication. Semaglutide and tirzepatide are approved peptide drugs. | |
503A Bulks List | Which bulk substances a licensed pharmacy may use to compound for a named patient | 21 CFR 216.23(a) lists six substances. None is a peptide [1]. | |
Advisory committee | Expert advice to FDA, not a rule | Six favorable recommendations and one rejection on July 23 and 24, 2026 [2]. | |
Category 2 interim policy | FDA's list of substances flagged for safety concerns | Twelve peptide substances were removed on April 15, 2026. Removal did not grant eligibility [3]. | |
Enforcement | Action against sellers whose claims point to human use | Five warning letters dated August 24, 2026, each citing website evidence of intended use [4]. | |
Product recalls | Quality failures in compounded products | Three voluntary recalls of compounded glutathione between August 5 and September 9, 2026, after elevated endotoxin findings. | |
Controlled substance scheduling | DEA schedules | CJC-1295, sermorelin and tesamorelin do not appear on the DEA list dated August 27, 2026. BPC-157 is not scheduled. | |
Sport anti-doping | What athletes may use | The 2026 WADA list is in force. The 2027 list was approved September 10, 2026 and takes effect January 1, 2027 [5]. |
The July 2026 committee vote in brief
FDA's Pharmacy Compounding Advisory Committee met at the White Oak campus on July 23 and 24, 2026. It considered seven peptide families under docket FDA-2025-N-6895 [2].
BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention. MOTS-c passed 7 to 5 with two abstentions. Semax and epitalon also passed. Emideltide, also called DSIP, failed 6 to 7 with one abstention [6].
Each peptide was reviewed for a narrow use that a nominator proposed. Those uses are not the ones most people know these compounds for online. A favorable vote for one proposed use says nothing about any other use.
Our full vote record covers the named dissent, the reasoning behind the emideltide result, and the evidence gaps FDA staff raised.
How the pathways fit together
Start with approval. An approved drug has passed FDA review for a specific use and is made under pharmaceutical manufacturing rules. Most of the research peptides named on this page have not reached that point.
Compounding is a different door. Section 503A lets a licensed pharmacy prepare a drug for an individual patient with a valid prescription. The pharmacy may only start from certain bulk ingredients. The 503A Bulks List is where those ingredients are listed, and the list can change only through rulemaking or an act of Congress.
The advisory committee sits in front of that door. It advises FDA on what to add. FDA then has to decide, draft a proposed rule, take public comment, and issue a final rule. No step after the vote has happened yet.
Anti-doping runs on its own track. WADA publishes its Prohibited List every year, and a substance can be banned in sport whether or not it is approved or compounded. A substance can also be fully lawful to prescribe and still be banned for athletes.
Research use only material is none of these. It is sold for laboratory work, and no vote on a bulks list makes it eligible for anything else. Our guide to what research use only means explains the label.
Timeline of the main actions
Date | What happened |
|---|---|
September 29, 2023 | FDA placed a group of peptides in Category 2 of its interim 503A policy, citing significant safety risks [3]. |
December 4, 2024 | The committee voted against adding any of five CJC-1295 forms to the bulks list. See Is CJC-1295 legal. |
April 15, 2026 | FDA announced the removal of 12 peptide substances from Category 2 [3]. |
April 16, 2026 | FDA published the Federal Register notice for the July committee meeting [7]. |
July 22, 2026 | The public docket for the July meeting closed to comments [2]. |
July 23 and 24, 2026 | The committee met and voted on seven peptides [2]. |
August 5 to September 9, 2026 | Three voluntary recalls of compounded glutathione, a tripeptide, followed endotoxin findings. |
August 24, 2026 | FDA dated five warning letters to online peptide sellers. FDA posted them on September 1 [4]. |
September 10 and 21, 2026 | WADA's Executive Committee approved the 2027 Prohibited List, and WADA published it eleven days later. |
January 1, 2027 | The 2027 WADA Prohibited List takes effect. |
Before the end of February 2027 | The committee is expected to meet again. No date had been posted when we checked. |
What to watch next
Three things are worth following. None of them has a fixed date.
- FDA's response to the vote. FDA has to decide whether to accept any recommendation. If it does, it must publish a proposed rule and take comment before anything is added to 21 CFR 216.23. We found no such notice on October 11, 2026.
- The second committee meeting. FDA said it would bring five more substances to the committee before the end of February 2027. They are cathelicidin LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF [3].
- The 2027 WADA list. It starts on January 1, 2027. Our 2027 WADA changes article covers what is new and what is not.
Our view on timing is simple. A finished rulemaking in 2026 looks very unlikely. Anyone quoting a specific month for legal compounding is guessing.
Where to check each fact yourself
We would rather you not take our word for any of this. These are the primary sources behind the table above.
Question | Where to look |
|---|---|
What is on the 503A Bulks List today? | The current text of 21 CFR 216.23, and FDA's 503A bulk drug substances page |
Has FDA published a rule or notice? | The Federal Register |
What did the committee vote on? | |
Is a substance still in Category 2? | FDA's Category 2 page |
Did FDA warn a seller? | FDA's warning letters database |
Is a substance banned in sport? | |
Is a substance a controlled substance? |
Common misreadings, corrected
What you may have heard | What the record shows |
|---|---|
"FDA approved six peptides." | No approval occurred. The committee gave non-binding advice about compounding eligibility. |
"BPC-157 can be compounded legally now." | 21 CFR 216.23(a) lists six substances and none is a peptide [1]. |
"Removal from Category 2 means these are allowed." | Removal lifted a safety flag. It did not grant eligibility [3]. |
"The vote made research peptides legal." | The vote concerned pharmacy ingredients. It did not change anything about research use only material. |
"WADA's 2027 list bans new peptides." | The announced change to S0 adds examples and guidance. It is not a new prohibition. See our 2027 article. |
Compound guides on this site
- Is BPC-157 legal in 2026, with the Category 2 and committee history.
- Is CJC-1295 legal, including the 2024 withdrawal and the committee vote.
- CJC-1295, sermorelin and tesamorelin, three related compounds with three different positions.
- AOD9604, its discontinued trial program and its WADA listing.
- The GLP-1 pipeline in 2026, for approved and in-development drugs.
- Which peptides are banned in sport, compound by compound.
How we keep this page current
Before we change any row, we reread the primary source linked above. We only update the date at the top after that check. Rows that depend on a linked article carry that article's own review date.
If you spot something out of date, tell us through our contact page. Our corrections policy explains how we handle errors.
References
- 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. 84 FR 4710, February 19, 2019. https://www.law.cornell.edu/cfr/text/21/216.23
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Food and Drug Administration. Warning Letters. Five letters dated August 24, 2026 to online peptide sellers, posted September 1, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
- World Anti-Doping Agency. The Prohibited List. https://www.wada-ama.org/en/prohibited-list
- The FDA Law Blog. The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List. July 28, 2026. https://www.thefdalawblog.com/2026/07/the-peptide-l-wave-rolls-on-pcac-adds-two-more-bulk-drug-substances-for-the-503a-list/
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register, April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
Research Use Only. 99 Purity Peptides supplies compounds for in vitro laboratory research only. Nothing sold here is for human or veterinary use. This page reports public regulatory records. It is not medical advice, legal advice, or guidance on using any product, and it makes no statement about the regulatory status of any particular company or product.
Frequently Asked Questions
Are peptides legal in the US in 2026?
It depends on the peptide and how it is sold. Some peptides are FDA-approved drugs. Most research peptides have no approval. Our guide on whether peptides are legal covers the federal rules and FDA's intended use test in full.
Did FDA approve BPC-157?
No. BPC-157 has no FDA approval for any indication. In July 2026 an advisory committee recommended it for the 503A Bulks List for one proposed use. That recommendation is non-binding and is not an approval.
Can pharmacies compound BPC-157 now?
Not under the 503A Bulks List. The current text of 21 CFR 216.23(a) names six substances, and none is a peptide. A substance can be added only through rulemaking or an act of Congress.
What is the 503A Bulks List?
It is the list of bulk drug substances a licensed pharmacy may use when it compounds a drug for an individual patient. It sits in 21 CFR 216.23. Being on the list is not an FDA approval.
What is Category 2?
Category 2 is part of FDA's interim policy. It held bulk substances that FDA flagged as raising significant safety concerns. On April 15, 2026, FDA announced the removal of 12 peptide substances from it. Removal did not make them eligible for compounding.
When will FDA make a final decision on the six peptides?
No deadline has been set, and FDA has not announced one. It would need to publish a proposed rule, take public comment, and issue a final rule. We found no proposed rule in the Federal Register on October 11, 2026.
Which peptides are on the WADA Prohibited List?
Several are named. BPC-157 appears in S0, AOD9604 in S2.2.3, CJC-1295 in S2.2.4, and MOTS-c in S4.4.1. Our WADA articles go compound by compound. Athletes should confirm any substance with their anti-doping organization.
Does the July 2026 vote change anything for research use only products?
No. The vote concerned which ingredients a licensed pharmacy may use. Research use only material is sold for laboratory work and is not made eligible for anything else by an advisory vote.
How often is this page updated?
We update it when a primary source changes, and the date at the top moves only after we recheck the sources listed on the page. If you see a row that looks out of date, contact us.
